Hubbry Logo
EthionamideEthionamideMain
Open search
Ethionamide
Community hub
Ethionamide
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Ethionamide
Ethionamide
Ethionamide
View on Wikipedia
from Wikipedia
Ethionamide
Clinical data
Trade namesTrecator, others
AHFS/Drugs.comMonograph
MedlinePlusa682402
Routes of
administration		by mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding~30%
Elimination half-life2 to 3 hours
Identifiers
  • 2-ethylpyridine-4-carbothioamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.007.846 Edit this at Wikidata
Chemical and physical data
FormulaC8H10N2S
Molar mass166.24 g·mol−1
3D model (JSmol)
Melting point164 to 166 °C (327 to 331 °F) (dec.)
  • S=C(c1ccnc(c1)CC)N
  • InChI=1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11) checkY
  • Key:AEOCXXJPGCBFJA-UHFFFAOYSA-N checkY
  (verify)

Ethionamide (aka ETA or ETH)[2] is an antibiotic used to treat tuberculosis.[3] Specifically it is used, along with other antituberculosis medications, to treat active multidrug-resistant tuberculosis.[3] It is no longer recommended for leprosy.[4][3] It is taken by mouth.[3]

Ethionamide has a high rate of side effects.[5] Common side effects include nausea, diarrhea, abdominal pain, and loss of appetite. Serious side effects may include liver inflammation and depression. It should not be used in people with significant liver problems. Use in pregnancy is not recommended as safety is unclear.[3] Ethionamide is in the thioamides family of medications. It is believed to work by interfering with the use of mycolic acid.[6]

Ethionamide was discovered in 1956 and approved for medical use in the United States in 1965.[6][3] It is on the World Health Organization's List of Essential Medicines.[7]

Medical uses

[edit]

Ethionamide is used in combination with other antituberculosis agents as part of a second-line regimen for active tuberculosis.[8]

The antimicrobial spectrum of ethionamide includes M. tuberculosis, M. bovis and M. smegmatis.[9] It also is used rarely against infections with M. leprae[10] and other nontuberculous mycobacteria such as M. avium[11] and M. kansasii.[8] While working in a similar manner to isoniazid, cross resistance is only seen in 13% of strains, since they are both prodrugs but activated by different pathways.[12]

Microbial resistance

[edit]

Resistance can emerge from mutations in ethA, which is needed to activate the drug, or ethR, which can be overexpressed to repress ethA. Mutations in inhA or the promoter of inhA can also lead to resistance through changing the binding site or overexpression.[5]

Adverse effects

[edit]

Ethionamide frequently causes gastrointestinal distress with nausea and vomiting which can lead patients to stop taking it.[13] This can sometimes be improved by taking it with food.[8]

Hepatotoxicity

[edit]

Ethionamide can cause hepatocellular toxicity and is contraindicated in patients with severe liver impairment. Patients on ethionamide should have regular monitoring of their liver function tests.[8] Liver toxicity occurs in up to 5% of patients and follows a pattern similar to isoniazid, usually arising in the first 1 to 3 months of therapy, but can occur even after more than 6 months of therapy. The pattern of liver function test derangement is often a rise in the ALT and AST.[14]

Neurotoxicity

[edit]

Both central neurological side effects such as psychiatric disturbances and encephalopathy, along with peripheral neuropathy have been reported.[8][11] Administering pyridoxine along with ethionamide may reduce these effects and is recommended.[8]

Thyrotoxicity

[edit]

Ethionamide is structurally similar to methimazole, which is used to inhibit thyroid hormone synthesis, and has been linked to hypothyroidism in several TB patients.[15] Periodic monitoring of thyroid function while on ethionamide is recommended.[8]

Interactions

[edit]

Ethionamide may worsen the adverse effects of other antituberculous drugs being taken at the same time. It boosts levels of isoniazid when taken together and can lead to increased rates of peripheral neuropathy and hepatotoxicity. When taken with cycloserine, seizures have been reported. High rates of hepatotoxicty have been reported when taken with rifampicin.[8] The drug's labeling cautions against excessive alcohol ingestion as it may provoke a psychotic reaction.[1]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Ethionamide is a prodrug[16] which is activated by the enzyme ethA, a mono-oxygenase in Mycobacterium tuberculosis, and then binds NAD+ to form an adduct which inhibits InhA in the same way as isoniazid. The mechanism of action is thought to be through disruption of mycolic acid.[6][17]

Expression of the ethA gene is controlled by ethR, a transcriptional repressor. It is thought that improving ethA expression will increase the efficacy of ethionamide and prompting interest by drug developers in EthR inhibitors as a co-drug.[5]

Pharmacokinetics

[edit]

Ethionamide is well absorbed orally with or without food, but is often administered with food to improve tolerance.[18][13]

It crosses the blood brain barrier to achieve concentrations in the cerebral-spinal fluid equivalent to plasma.[13]

Other names

[edit]

It is sold under the brand name Trecator[1] by Wyeth Pharmaceuticals which was purchased by Pfizer in 2009.[citation needed]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Ethionamide

View on Grokipedia
from Grokipedia
Ethionamide is a thioamide used as a second-line agent in the treatment of active caused by , particularly in cases resistant to isoniazid or rifampin or when patients are intolerant to other antitubercular drugs. It must always be administered in combination with at least one other effective antitubercular agent to prevent the emergence of resistance. Chemically known as 2-ethylthioisonicotinamide, it is a , crystalline, nonhygroscopic with a of 162°C and a faint to moderate odor; it is practically insoluble in but soluble in and . Ethionamide functions as a prodrug that requires bioactivation by the mycobacterial monooxygenase EthA to exert its bactericidal or bacteriostatic effects, primarily by inhibiting the enoyl-acyl carrier protein reductase (InhA), a key in the synthesis of mycolic acids essential for the mycobacterial . This mechanism is analogous to that of isoniazid, though ethionamide targets a distinct pathway, making it effective against some isoniazid-resistant strains. The drug was first approved by the U.S. in 1965 under the brand name Trecator and has since become a cornerstone in regimens for (MDR-TB) as recommended by the . It is rapidly absorbed after , extensively metabolized in the liver, and has a plasma of approximately 2 hours, with less than 1% excreted unchanged in the urine. Clinical use of ethionamide involves dosing at 15–20 mg/kg/day for adults (maximum 1 g/day), often divided into two or three doses and taken with food to minimize gastrointestinal side effects; pediatric dosing is similar at 10–20 mg/kg/day. It is contraindicated in patients with severe hepatic impairment or hypersensitivity to the drug and requires careful monitoring for hepatotoxicity, as clinical hepatotoxicity occurs in approximately 5% of patients. Common adverse reactions include anorexia, nausea, vomiting, and metallic taste, while serious effects may encompass hepatitis, hypothyroidism, optic neuritis, and psychiatric disturbances. Due to its role in MDR-TB therapy, ethionamide is classified as a Group C drug in WHO guidelines, reserved for cases where shorter regimens or more potent agents are insufficient.

Medical uses

Indications in tuberculosis

Ethionamide serves as a second-line oral primarily indicated for the treatment of active (TB) in combination with other antitubercular agents, especially when first-line drugs like isoniazid are ineffective due to resistance or intolerance. It is recommended for use only after susceptibility testing confirms Mycobacterium tuberculosis resistance to isoniazid or rifampin, and it must be administered alongside at least one or two other effective drugs to prevent further resistance development. In multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), ethionamide is incorporated into individualized longer regimens (typically 18-24 months) or shorter all-oral options when higher-priority drugs are unavailable or contraindicated. As of the 2025 WHO consolidated guidelines (Module 4 update), the preferred treatment for eligible patients with MDR/RR-TB (including pre-XDR-TB) is a new all-oral 6-month regimen consisting of , delamanid, , a fluoroquinolone (levofloxacin or ), and (BDLLfxC). For cases unsuitable for this regimen (e.g., fluoroquinolone resistance), modified 9-month all-oral regimens may be used conditionally in patients with limited disease and no prior exposure to key second-line drugs. These include an intensive phase of 4 months (extendable to 6 if smear-positive) with , a fluoroquinolone (levofloxacin or ), ethionamide (or ), , ethambutol, high-dose isoniazid, and pyrazinamide, followed by a 5-month continuation phase of the fluoroquinolone, , ethambutol, and pyrazinamide; may substitute for ethionamide in certain cases, such as . The (WHO) classifies ethionamide as a Group C agent for MDR/RR-TB management in longer individualized regimens, to be used when drugs from Groups A (e.g., levofloxacin, , ) and B (e.g., , ) cannot be included. These shorter regimens are supported by WHO guidelines based on showing comparable treatment success rates to longer options in selected populations, though with very low certainty for some outcomes. Standard dosing for adults is 15-20 mg/kg/day (maximum 1 g/day), given in 2-4 divided doses after meals to reduce gastrointestinal intolerance, with treatment durations of at least 6-24 months tailored to the resistance profile and clinical response. Initiation typically begins at 250 mg once daily for 1-2 days, followed by gradual increases to the full dose over 1-2 weeks to enhance tolerability. For pediatric patients over 12 years, the dose is similar at 10-20 mg/kg/day in 2-3 divided doses (maximum 1 g/day), though use in younger children is limited to severe cases of resistant TB with imminent life-threatening complications. Monitoring during ethionamide therapy requires baseline and monthly to detect potential early, along with periodic assessments of thyroid function, blood glucose, and vision, as part of standard WHO-recommended for second-line TB drugs.

Microbial resistance

Resistance to ethionamide in primarily arises from mutations in the ethA , which encodes the monooxygenase responsible for activating the , or in the inhA , which encodes the enoyl-acyl carrier protein reductase targeted by the , resulting in reduced drug or impaired binding to the target. Additional mechanisms include mutations in the ethR , leading to overexpression that represses ethA, as well as upregulation or alterations that contribute to lower-level resistance. Cross-resistance between ethionamide and isoniazid is common due to their shared target at InhA, particularly from promoter in inhA (such as -15T), which confer low-level resistance to both drugs; this occurs in approximately 15-30% of multidrug-resistant TB (MDR-TB) isolates, depending on regional prevalence of inhA . In contrast, high-level isoniazid resistance driven by katG typically does not confer cross-resistance to ethionamide, as the activation pathways differ. Ethionamide resistance is uncommon in drug-susceptible TB strains (prevalence not routinely surveyed but low based on limited testing data) but increases significantly in MDR-TB and extensively drug-resistant TB (XDR-TB) contexts, where rates can reach 20-30% due to cross-resistance and acquired mutations, as reported in WHO surveillance data and regional studies. Higher incidence is observed in previously treated patients and high-burden areas like and . To prevent the emergence and spread of resistance, ethionamide should always be used as part of multidrug combination regimens for drug-resistant TB, as recommended by WHO guidelines, to minimize selective pressure on monotherapy. Susceptibility testing is essential prior to initiation, employing phenotypic methods such as (MIC) determination via BACTEC MGIT 960 or the agar proportion method, or genotypic approaches like line probe assays and targeted sequencing for ethA, ethR, and inhA mutations. Ethionamide resistance adversely affects treatment outcomes in MDR-TB, with success rates dropping to 50-70% in resistant cases compared to over 80% in susceptible MDR-TB cohorts, due to limited alternative options and increased regimen complexity; acquired resistance during further elevates the risk of poor outcomes, including treatment failure or .

Contraindications and special populations

Hepatic and renal impairment

Ethionamide is contraindicated in patients with severe hepatic impairment, such as active or , due to the high risk of and potentially fatal . In cases of moderate hepatic impairment, ethionamide should be used with caution as a relative ; therapy may be initiated at a reduced dose of 250 mg daily, with gradual based on tolerance, while closely monitoring (LFTs) weekly to detect early signs of elevation. For renal impairment, no routine dose adjustment is required, as ethionamide is primarily eliminated via hepatic and biliary routes with minimal renal excretion; however, caution is advised in severe cases (creatinine clearance <30 mL/min) owing to the potential accumulation of active metabolites, and some guidelines recommend limiting the dose to 250-500 mg daily in such patients. Baseline assessment of hepatic function, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), is essential prior to starting ethionamide, with ongoing monitoring every 2-4 weeks during treatment; discontinuation is recommended if levels exceed five times the upper limit of normal (ULN), particularly if accompanied by symptoms of hepatitis. According to joint guidelines from the American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America (IDSA), ethionamide should be avoided in patients with decompensated liver disease, and alternative agents such as linezolid may be preferred to minimize hepatotoxicity risk in multidrug-resistant tuberculosis regimens.

Use in pregnancy and lactation

Ethionamide is classified as FDA Pregnancy Category C, indicating that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans. In animal studies, ethionamide demonstrated teratogenic potential in rabbits and rats at doses exceeding the human therapeutic dose of 15-20 mg/kg/day, resulting in embryotoxicity and congenital malformations. Human data on ethionamide use during pregnancy are limited, with some reports suggesting an increased risk of congenital anomalies, including central nervous system defects, though causality remains unestablished due to small sample sizes and confounding factors in multidrug regimens for tuberculosis. According to WHO and ATS/CDC/IDSA recommendations, ethionamide is generally contraindicated during pregnancy due to these risks; however, it may be used in multidrug-resistant tuberculosis (MDR-TB) cases only if the potential benefits outweigh the risks to the fetus, accompanied by close monitoring through serial ultrasounds to assess fetal development. During lactation, ethionamide distribution into breast milk occurs in unknown amounts, with minimal data available on excretion levels. Breastfeeding is not recommended while taking ethionamide, owing to the potential for gastrointestinal upset in the infant from drug exposure and the risk of tuberculosis transmission through close contact with an infected mother, despite no evidence of transmission via milk itself. For pregnant patients with MDR-TB, alternatives to ethionamide include regimens incorporating linezolid as a direct replacement in shorter regimens, bedaquiline or , as supported by the 2022 WHO guidelines, which prioritize safer options in this population based on emerging data showing favorable maternal and fetal outcomes without increased malformation rates. Postpartum, ethionamide can be resumed if required for ongoing MDR-TB treatment, but patients should receive counseling on contraception due to the drug's association with menstrual irregularities, which may affect fertility and contraceptive efficacy.

Adverse effects

Common side effects

The most frequent adverse reactions to ethionamide are gastrointestinal disturbances, affecting a substantial proportion of patients and often impacting treatment adherence. These include nausea, vomiting, diarrhea, abdominal pain, anorexia, and a metallic taste in the mouth, with incidences reported as high as 50% for intolerance to standard single doses and up to 63% for nausea and/or vomiting in clinical cohorts of multidrug-resistant tuberculosis patients. Excessive salivation is also common, occurring in 1% to 10% of cases. Other common mild effects encompass dermatological reactions such as acne and rash, which are reported in post-marketing surveillance and clinical use but with lower documented incidences, typically resolving with continued therapy or supportive measures. These symptoms generally onset within the first few weeks of treatment and are dose-dependent, with gastrointestinal intolerance leading to dose adjustments or interruptions in approximately 20% to 50% of affected individuals across studies. Management strategies focus on improving tolerability, including administration with meals or at bedtime to reduce gastrointestinal upset, use of antiemetics for nausea and vomiting, and gradual dose escalation. Prophylactic supplementation with (vitamin B6) is recommended to mitigate potential peripheral neuropathy, particularly in patients over 40 years old or those on prolonged therapy. Patient education emphasizes reporting persistent symptoms promptly, as many effects diminish over time with adherence to these approaches.

Serious adverse effects

Ethionamide is associated with hepatotoxicity, manifesting as elevated liver enzymes, jaundice, and hepatitis in treated patients. Transient elevations in transaminases occur frequently, while clinically apparent acute liver injury arises in up to 5% of patients and can be severe or fatal. The mechanism involves an idiosyncratic reaction, likely related to reactive metabolites formed during hepatic metabolism. Management requires monthly monitoring of liver function tests, with discontinuation recommended if alanine aminotransferase (ALT) exceeds three times the upper limit of normal accompanied by symptoms such as jaundice or abdominal pain. Neurotoxicity represents another serious concern, including peripheral neuropathy, optic neuritis, depression, and psychosis. These effects are linked to vitamin B6 (pyridoxine) deficiency induced by ethionamide's interference with pyridoxine metabolism. Prophylactic treatment with pyridoxine at 100-200 mg daily is recommended to prevent or mitigate these toxicities, particularly when ethionamide is combined with other neurotoxic agents like isoniazid. Thyroid dysfunction, primarily hypothyroidism, occurs in up to 30% of patients on ethionamide-containing regimens, often presenting with goiter and elevated thyroid-stimulating hormone (TSH) levels. This adverse effect stems from ethionamide's inhibition of thyroid hormone synthesis, akin to its structural analog methimazole. Periodic monitoring of thyroid function every 6 months is advised, with thyroxine supplementation as needed for confirmed cases. Other serious adverse effects include hypersensitivity reactions such as rash, thrombocytopenia, and purpura, as well as alopecia and gynecomastia; seizures and encephalopathy are rare but reported. Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis, have been reported, particularly in antitubercular combination regimens. Adverse events associated with ethionamide lead to its discontinuation in approximately 7% (95% CI 4-10%) of patients in meta-analyses of multidrug-resistant tuberculosis treatment.

Drug interactions

Interactions with antitubercular agents

Ethionamide is frequently administered in combination with other antitubercular agents for multidrug-resistant tuberculosis (MDR-TB) therapy, where pharmacokinetic and pharmacodynamic interactions can influence efficacy and safety. These interactions often potentiate adverse effects, necessitating careful monitoring and dose adjustments to optimize treatment outcomes. Concomitant use with isoniazid elevates serum isoniazid concentrations, contributing to an additive risk of hepatotoxicity due to the structural similarity and shared metabolic pathways of both drugs. Clinical studies in MDR-TB patients demonstrate hepatotoxicity-related adverse events, including elevated liver enzymes and jaundice, when ethionamide is combined with isoniazid. To mitigate this, liver function tests should be monitored closely, particularly in patients with preexisting hepatic risk factors, and doses spaced apart if feasible to reduce peak exposure overlap. The combination of ethionamide and cycloserine heightens neurotoxicity, with reports of convulsions, psychosis, and other central nervous system effects due to synergistic inhibition of gamma-aminobutyric acid activity. Evidence from observational studies in MDR-TB regimens indicates increased incidence of neuropsychiatric symptoms, such as anxiety and hallucinations, prompting recommendations for pyridoxine supplementation and vigilant symptom surveillance. If neurotoxic symptoms emerge, cycloserine dosing should be reduced by 250 mg daily, with potential discontinuation if unresolved. Administration with para-aminosalicylic acid (PAS) may amplify hypothyroidism risk, though no cross-resistance occurs between the agents. Additionally, this pairing can amplify hypothyroidism risk, warranting thyroid function monitoring. Ethionamide is often combined with fluoroquinolones, such as levofloxacin, in MDR-TB regimens, contributing to improved treatment success rates without notable pharmacokinetic alterations. Meta-analyses of clinical trials confirm improved cure rates (up to 70-80% in fluoroquinolone-inclusive combinations) compared to non-synergistic alternatives, underscoring their role as core components of shorter MDR-TB protocols.

Interactions with other drugs

Ethionamide interacts with alcohol, potentiating both hepatotoxicity and the risk of psychotic reactions such as hallucinations, abnormal thinking, and personality changes. This interaction is classified as major in severity, and strict abstinence from alcohol is recommended during treatment to minimize these risks. The absorption of ethionamide is not significantly affected by aluminum- or magnesium-based antacids, with pharmacokinetic studies showing minimal changes in peak plasma concentrations, area under the curve, or time to maximum concentration when coadministered. Coadministration of ethionamide with can increase the risk or severity of bleeding due to enhanced anticoagulant effects, requiring adjustment of warfarin dosing and frequent monitoring of international normalized ratio (INR). Ethionamide should be avoided or used with extreme caution in combination with other hepatotoxic drugs, as this can lead to additive liver injury evidenced by elevated transaminases in case reports; examples include and certain statins, where liver function tests must be monitored closely.

Pharmacology

Pharmacodynamics

Ethionamide is a prodrug that requires bioactivation within to exert its antitubercular effects. The activation occurs via the bacterial monooxygenase EthA (encoded by Rv3854c), which oxidizes ethionamide to an S-oxide intermediate; this reactive metabolite then forms a covalent adduct with the NAD⁺ cofactor, potently inhibiting InhA, the enoyl-acyl carrier protein (ACP) reductase. InhA is a key enzyme in the type II fatty acid synthase (FAS-II) system, catalyzing the reduction of enoyl-ACP substrates during the elongation of fatty acids. By inhibiting InhA, ethionamide disrupts the biosynthesis of mycolic acids, long-chain α-alkyl-β-hydroxy fatty acids that are essential components of the mycobacterial cell wall. This interference impairs cell wall integrity, resulting in the loss of acid-fastness and increased permeability, ultimately leading to bacterial death. Ethionamide exhibits bactericidal activity at higher concentrations but is generally bacteriostatic under typical therapeutic conditions. Ethionamide's spectrum of activity is primarily limited to mycobacteria, with strong efficacy against M. tuberculosis (including multidrug-resistant strains). For susceptible M. tuberculosis strains, the minimum inhibitory concentration (MIC) ranges from 0.5 to 2.5 μg/mL, depending on the assay method. It shows no significant activity against Gram-negative bacteria due to the absence of the specific activation and target machinery. Resistance to ethionamide often stems from mutations in the ethA gene, which impair the enzyme's ability to activate the prodrug, thereby preventing formation of the inhibitory NAD⁺ adduct and preserving InhA function. Additional resistance mechanisms may involve promoter mutations in ethR (a repressor of ethA) or alterations in inhA that reduce adduct binding affinity.

Pharmacokinetics

Ethionamide exhibits rapid and nearly complete oral absorption, with a bioavailability of approximately 100% and no significant first-pass metabolism. Peak plasma concentrations (Cmax) of around 2 μg/mL are typically achieved 1 to 2 hours after a 250–500 mg dose in conditions. Administration with food has minimal impact on the extent of absorption (AUC reduced by only 4–9%) but may slightly prolong the time to peak concentration (Tmax) to 2–3 hours, allowing it to be taken with meals to mitigate gastrointestinal side effects. The drug distributes widely throughout body tissues and fluids, achieving therapeutic concentrations in the lungs and penetrating the even in the absence of meningeal . Ethionamide demonstrates moderate protein binding of about 30% and an apparent (Vd) of approximately 1.3 L/kg, reflecting its extensive tissue penetration. occurs primarily in the liver through flavin-containing monooxygenases, which oxidize ethionamide to its active sulfoxide metabolite and inactive sulfone derivatives, among others. The plasma elimination is short, ranging from 1.9 to 3 hours, necessitating multiple daily dosing for sustained efficacy. Excretion is predominantly non-renal, with metabolites eliminated mainly via the biliary route into (accounting for 60–80% of the dose) and minimal renal clearance (less than 10%, including <1% as unchanged drug). Consequently, no dosage adjustment is required for patients with mild renal impairment. Pharmacokinetic variability is notable across populations, with lower systemic exposure observed in children (due to higher clearance) and in those with HIV co-infection compared to HIV-uninfected adults; a target Cmax of 2–5 μg/mL is associated with optimal antitubercular .

Chemical properties

Structure and synthesis

Ethionamide has the systematic IUPAC name 2-ethylpyridine-4-carbothioamide, with the molecular formula C₈H₁₀N₂S and a molecular weight of 166.24 g/mol. It is classified as a thioamide derivative of isonicotinic acid, characterized by a pyridine ring bearing a thioamide group (-C(S)NH₂) at the 4-position and an ethyl substituent (-CH₂CH₃) at the 2-position. This structural arrangement positions the thioamide functionality para to the nitrogen in the pyridine ring, akin to isonicotinic acid derivatives, while the ethyl group enhances lipophilicity compared to unsubstituted analogs. The molecule is achiral, lacking any stereogenic centers or elements that would produce optically active isomers of clinical relevance. Ethionamide is a of isoniazid (isonicotinohydrazide), featuring a comparable pyridine-4-carbothioamide scaffold but with a thioamide instead of a and the addition of the 2-ethyl group; this similarity underlies the cross-resistance between the two drugs, particularly through shared targeting of biosynthesis pathways after metabolic activation. Ethionamide is typically synthesized by thionation of 2-ethylpyridine-4-carboxamide using or similar agents. Industrial-scale production, as detailed in a , employs routes involving intermediates derived from isonicotinic acid, such as to introduce the and subsequent thioamide formation.

Physical and chemical characteristics

Ethionamide appears as a yellow to pale yellow crystalline powder with a faint to moderate sulfide-like . The compound is practically insoluble in (approximately 0.84 mg/mL) and , but soluble in and , and slightly soluble in . Its pKa value is approximately 4.37, associated with the nitrogen, while the carbothioamide group contributes to its ionization behavior in solution. Ethionamide exhibits a logP (octanol/water partition coefficient) of 0.37, indicating low that supports its profile and potential for tissue distribution despite limited partitioning into . The drug is nonhygroscopic and stable under normal conditions but darkens upon exposure to light, necessitating protection from light during handling. It should be stored in tight, airtight containers at (20–25°C), away from moisture to prevent oxidative degradation. In solution, ethionamide is prone to oxidation, degrading to its , which reduces potency and requires careful to maintain stability. These properties influence its , where ethionamide is typically available as 250 mg film-coated tablets for . The compound's structural thioamide moiety, derived from isonicotinamide, underpins its moderate in organic solvents, facilitating tablet manufacturing.

History

Discovery

Ethionamide was discovered in 1956 by French chemists at Société des Usines Chimiques Rhône-Poulenc through systematic screening of thioisonicotinamide derivatives for antitubercular properties. This effort was inspired by the success of isoniazid, introduced in 1952 as a frontline antitubercular agent, prompting exploration of structural analogs to address emerging resistance. Initial studies demonstrated ethionamide's activity against , with preliminary reports highlighting its comparable efficacy to isoniazid in inhibiting bacterial growth. These findings established ethionamide as a promising thioamide , capable of disrupting essential bacterial processes. Preclinical evaluation advanced to animal models, where ethionamide proved effective in guinea pigs infected with M. tuberculosis. The research culminated in a patent filing in 1958 (British Patent 800,250).

Development and approval

Ethionamide entered clinical development shortly after its synthesis in 1956 as a thioamide analog of isoniazid, aimed at addressing strains resistant to first-line agents. Early human studies in the late and early , including initial safety assessments and small-scale efficacy evaluations, confirmed its activity against but highlighted significant gastrointestinal side effects, such as and , limiting tolerability. These trials involved limited patient cohorts and focused on establishing basic and dosing, with ethionamide demonstrating bactericidal effects when combined with other antitubercular drugs. Subsequent phase III trials in the 1960s, conducted across multiple countries including the and , evaluated ethionamide's role in retreatment regimens for patients with drug-resistant . These multinational studies, often involving combinations with isoniazid or , reported cure rates of 70-80% in adherent patients, with sputum conversion rates supporting its adjunctive use in multidrug therapy. The trials underscored ethionamide's effectiveness against isoniazid-resistant strains but reinforced concerns over toxicity, including and , which influenced its positioning as a second-line agent. The U.S. (FDA) approved ethionamide in 1965 under the brand name Trecator for use as adjunctive therapy in active pulmonary cases resistant to first-line drugs or in patients intolerant to them, requiring combination with at least one other effective agent to prevent rapid resistance development. The (WHO) first included ethionamide on its Model List of in 1982 for treatment, though it was temporarily removed in 1987 before being reinstated in subsequent lists due to its critical role in resource-limited settings. Post-approval, ethionamide's integration into (MDR-TB) guidelines began in the 1990s, with early WHO recommendations emphasizing its use in individualized regimens for resistant cases. By the 2000s, it became a core component of second-line protocols, though its high profile—manifesting as frequent adverse events in up to 50% of patients—restricted it to second-line status and prompted ongoing monitoring for safer alternatives. In 2022, WHO updated its consolidated guidelines on drug-resistant TB treatment to endorse shorter 9-month all-oral regimens incorporating ethionamide (or prothionamide) alongside drugs like levofloxacin, , and for fluoroquinolone-susceptible MDR/RR-TB, aiming to improve completion rates while maintaining efficacy above 85% in eligible patients. As of 2025, ongoing research has focused on enhancing ethionamide's utility through combinations, such as with alpibectir, which boosts its activity and allows lower doses to reduce toxicity. In August 2025, the granted designation to this combination for treatment, with Phase 2 clinical trials evaluating its early bactericidal activity, safety, and tolerability. No new therapeutic indications have been approved for ethionamide since its initial authorization, reflecting its established niche in resistant TB management.

Society and culture

Brand names and formulations

Ethionamide was commercially available under the primary brand name Trecator in the United States, originally developed and marketed by Lederle Laboratories, a division of Pharmaceuticals, which was acquired by in 2009. However, discontinued manufacturing of Trecator in 2025, with supplies exhausted by September 2025, leaving ethionamide no longer commercially available in the . Generic versions have not been approved in the , though patents expired in the 1970s. Internationally, generic versions are available. Internationally, ethionamide is sold under various brand names, including Ethimide in and several markets in , Isotamide and Ethide in , and Ethomid in other regions. A sustained-release variant was marketed as Trecator-SC in select countries, though it has also been discontinued in the . The standard is 250 mg film-coated oral tablets, which are orange in color and scored for dose splitting to allow for flexible dosing. No liquid, intravenous, or other parenteral forms are available. For pediatric use, a 125 mg dispersible tablet exists in some global supply chains. Fixed-dose combination products, such as those combining ethionamide with , are offered in certain markets to simplify multidrug regimens for drug-resistant . Major manufacturers include the original producer (now ) for Trecator, with generics produced by companies such as Macleods Pharmaceuticals, Micro Labs Ltd., and , many of which are prequalified by the for global distribution. In low-income countries, ethionamide is accessible through the Global Drug Facility (GDF) at a cost of approximately $0.09–0.13 per 250 mg tablet, depending on pack size and formulation, facilitating affordable treatment for programs (as of January 2025). Ethionamide is classified as a prescription-only in major regulatory jurisdictions. In the United States, it was available solely by prescription from a licensed healthcare provider, as indicated in its FDA-approved labeling for treatment in combination with other antitubercular agents; however, following the discontinuation, it is no longer available domestically. In , ethionamide falls under of the Drugs and Cosmetics Rules, 1945, requiring it to be sold only on the prescription of a registered medical practitioner to ensure appropriate use in therapy. Globally, it is recognized on the World Health Organization's (WHO) Model List of (24th edition, ) as a complementary medicine for (MDR-TB), underscoring its role in standard treatment protocols for resistant strains. Ethionamide's availability is facilitated through international mechanisms like the Stop TB Partnership's Global Drug Facility (GDF), which supplies quality-assured formulations to programs in over 140 countries, including dispersible pediatric versions since 2018 to support child-friendly dosing. Despite this, intermittent shortages occurred between 2020 and 2022, driven by disruptions, manufacturing halts at key producers, and heightened demand during the , which affected access in several regions; the recent US discontinuation may exacerbate global supply concerns. Access to ethionamide varies by setting and funding. Through WHO-endorsed programs and the GDF, it is provided at no cost to eligible low- and middle-income countries, enabling free distribution within national TB control efforts. In unsubsidized private markets, however, a full treatment course (typically 6–24 months at 15–20 mg/kg daily) can cost $500–$1,000, reflecting generic pricing and variations, though exact figures depend on regimen length and local . Regulatory milestones include WHO prequalification of ethionamide formulations starting in , ensuring quality standards for global procurement. Since 2018, it has been incorporated into WHO-recommended pediatric MDR-TB regimens, with the availability of a 125 mg dispersible tablet improving and adherence in children under 25 kg. The original patent for ethionamide, developed in the mid-20th century, expired in the 1970s, paving the way for widespread generic manufacturing internationally and reducing barriers to production. Nonetheless, challenges persist with generic quality, as substandard anti-TB medicines have been identified in surveys; the WHO Prequalification Programme actively assesses and lists compliant products to mitigate risks like variable efficacy and safety.

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/013026s029lbl.pdf
  2. https://www.ncbi.nlm.nih.gov/books/NBK548025/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC6260165/
  4. https://www.fda.gov/media/166142/download
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7038277/
  6. https://www.who.int/news-room/questions-and-answers/item/tuberculosis-multidrug-resistant-tuberculosis-%28mdr-tb%29
  7. https://www.who.int/news/item/15-04-2025-who-announces-landmark-changes-in-treatment-of-drug-resistant-tuberculosis
  8. https://www.who.int/publications/i/item/9789240107243
  9. https://tbksp.who.int/en/node/3036
  10. https://www.ncbi.nlm.nih.gov/books/NBK588562/
  11. https://www.drugs.com/dosage/ethionamide.html
  12. https://www.who.int/publications/i/item/9789240063129
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC8868424/
  14. https://journals.asm.org/doi/full/10.1128/aac.47.12.3799-3805.2003
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC6636829/
  16. https://www.nature.com/articles/s42003-023-04433-w
  17. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0135003
  18. https://journals.asm.org/doi/10.1128/aac.01028-15
  19. https://www.dovepress.com/genetic-characterization-conferred-co-resistance-to-isoniazid-and-ethi-peer-reviewed-fulltext-article-IDR
  20. https://www.ncbi.nlm.nih.gov/books/NBK539502/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC4743335/
  22. https://etd.library.emory.edu/concern/etds/9019s3716?locale=it
  23. https://publications.ersnet.org/content/erj/48/3/946
  24. https://reference.medscape.com/drug/trecator-sc-ethionamide-342695
  25. https://extranet.who.int/prequal/sites/default/files/whopar_files/TB133part4v1.pdf
  26. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm
  27. https://www.atsjournals.org/doi/10.1164/rccm.201909-1874ST
  28. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/13026s022%2C023lbl.pdf
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC3354680/
  30. https://www.drugs.com/monograph/ethionamide.html
  31. https://www.ncbi.nlm.nih.gov/books/NBK501597/
  32. https://publications.aap.org/pediatriccare/drug-monograph/18/5279/Ethionamide
  33. https://seimc.org/wp-content/uploads/2025/05/seimc-dc-2024-Guia-ManejoTuberculosis-Resistente.pdf
  34. https://www.ncbi.nlm.nih.gov/books/NBK613101/
  35. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540217/all/Ethionamide
  36. https://www.ncbi.nlm.nih.gov/books/NBK247415/bin/part3-m9.pdf
  37. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/013026s032lbl.pdf
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC8448124/
  39. https://www.drugs.com/sfx/ethionamide-side-effects.html
  40. https://www.inchem.org/documents/pims/pharm/ethionam.htm
  41. https://www.sciencedirect.com/science/article/abs/pii/S0041387962800543
  42. https://www.thoracic.org/statements/resources/mtpi/hepatotoxicity-of-antituberculosis-therapy.pdf
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC6852705/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC5007858/
  45. https://www.nejm.org/doi/full/10.1056/NEJM200506303522621
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC7384398/
  47. https://journals.asm.org/doi/10.1128/aac.00278-21
  48. https://go.drugbank.com/drugs/DB00260
  49. https://journals.asm.org/doi/10.1128/spectrum.01437-25
  50. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540149/all/Cycloserine
  51. https://medicalguidelines.msf.org/en/viewport/TUB/english/ethionamide-eto-or-prothionamide-pto-20324029.html
  52. https://www.sciencedirect.com/science/article/abs/pii/S0223523418308109
  53. https://www.ncbi.nlm.nih.gov/books/NBK247431/
  54. https://www.drugs.com/food-interactions/ethionamide.html
  55. https://journals.asm.org/doi/10.1128/aac.02167-19
  56. https://pubmed.ncbi.nlm.nih.gov/11181366/
  57. https://go.drugbank.com/drugs/DB00682
  58. https://www.drugs.com/drug-interactions/ethionamide.html
  59. https://www.drugs.com/drug-interactions/ethionamide-with-ketoconazole-1048-0-1412-0.html
  60. https://go.drugbank.com/drugs/DB00609
  61. https://pubmed.ncbi.nlm.nih.gov/23215813/
  62. https://pubchem.ncbi.nlm.nih.gov/compound/Ethionamide
  63. https://www.chemicalbook.com/ProductChemicalPropertiesCB1292374_EN.htm
  64. https://www.sciencedirect.com/science/article/abs/pii/S0065774308606508
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC9582839/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC1939055/
  67. https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.201509-632PS
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC4526730/
  69. https://www.sciencedirect.com/science/article/abs/pii/S0041387964800453
  70. https://www.nejm.org/doi/full/10.1056/NEJMra1205429
  71. https://cdek.pharmacy.purdue.edu/api/102821/
  72. https://list.essentialmeds.org/medicines/351/print?format=pdf
  73. https://tbksp.who.int/en/node/2977
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC9489134/
  75. https://www.biospace.com/press-releases/bioversys-receives-ema-orphan-designation-for-the-combination-of-alpibectir-and-ethionamide-for-the-treatment-of-tuberculosis
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC12582603/
  77. https://www.drugs.com/drug-shortages/ethionamide-tablet-87
  78. https://www.medindia.net/drugs/trade-names/ethionamide.htm
  79. https://www.drugs.com/ingredient/ethionamide.html
  80. https://www.stoptb.org/sites/default/files/documents/2024.12.16_tb_medicines_budgeting_prices_jan_2025_KL.pdf
  81. https://extranet.who.int/prequal/sites/default/files/whopar_files/TB242part6.pdf
  82. https://www.pharmacompass.com/manufacturers-suppliers-exporters/ethionamide
  83. https://drugscontrol.py.gov.in/sites/default/files/2023-03/Schedule-h_0.pdf
  84. https://list.essentialmeds.org/medicines/351
  85. https://www.stoptb.org/sites/default/files/documents/2024.11.25_gdf_medicines_catalog_Nov_2024.pdf
  86. https://www.nature.com/articles/s41599-024-03759-y
  87. https://www.stoptb.org/sites/default/files/documents/2024.10.02_tb_medicines_budgeting_prices_oct_2024.pdf
  88. https://academic.oup.com/jac/article/72/4/1243/2884272
  89. https://tbksp.who.int/en/node/1776
  90. https://www.fda.gov/media/105829/download
  91. https://extranet.who.int/prequal/sites/default/files/whopar_files/TB352part6v2.pdf
  92. https://extranet.who.int/prequal/sites/default/files/document_files/TBQuality-Survey_Nov2011.pdf
Add your contribution
Related Hubs
User Avatar
No comments yet.